bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) is one of 38 public companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare bioAffinity Technologies to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Risk and Volatility
bioAffinity Technologies has a beta of 3.93, suggesting that its share price is 293% more volatile than the S&P 500. Comparatively, bioAffinity Technologies’ competitors have a beta of 5.71, suggesting that their average share price is 471% more volatile than the S&P 500.
Earnings and Valuation
This table compares bioAffinity Technologies and its competitors top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
bioAffinity Technologies | $2.53 million | -$7.94 million | -3.10 |
bioAffinity Technologies Competitors | $1.61 billion | $106.61 million | -0.59 |
Institutional & Insider Ownership
1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Commercial physical research” companies are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 16.7% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings and target prices for bioAffinity Technologies and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
bioAffinity Technologies | 0 | 0 | 0 | 0 | N/A |
bioAffinity Technologies Competitors | 50 | 811 | 1288 | 31 | 2.60 |
As a group, “Commercial physical research” companies have a potential upside of 12.15%. Given bioAffinity Technologies’ competitors higher possible upside, analysts plainly believe bioAffinity Technologies has less favorable growth aspects than its competitors.
Profitability
This table compares bioAffinity Technologies and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
bioAffinity Technologies | -313.34% | -107.20% | -84.10% |
bioAffinity Technologies Competitors | -259.99% | -16.80% | -11.21% |
Summary
bioAffinity Technologies competitors beat bioAffinity Technologies on 9 of the 10 factors compared.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.